TNFSF14 and respiratory failure: CERC-002 significantly increased the number of CARDS patients free of respiratory failure by day 28 (NCT04412057).40 CERC-002 inhibits LIGHT, which drives inflammation, T-cell proliferation and cytokine release, contributing to tissue damage and fibrosis.38 40 LIGHT levels are raised in COVID-19 patients and serum concentration is proportional to infection severity, hence its inhibition may mitigate propagation of the cytokine storm and CARDS progression.